why choose us

First received: March 16, 2023

Clinical Trial: Remaxol® in Patients With Drug-induced Liver Injuries During Antitumor Therapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cancer

Study Type: OBSERVATIONAL


Official Title: Non-interventional, Prospective Study of Safety and Efficiency of the Drug Remaxol® (NTFF POLYSAN Ltd., Russia) in Patients With Drug-induced Liver Injuries During Antitumor Therapy.

Brief Summary: Cancer has moved from the tenth place to the second one over the last 100 years, being inferior to only cardiovascular diseases in morbidity and mortality.40 % of hepatitis cases in patients older than 40 years and 25 % of cases of fulminant hepatic failure (FHF) are caused by drug hepatic toxicity.Cases of acute drug-induced hepatitis (ADIH) make 15-20 % of patients with fulminant hepatitis in Western Europe.

Read more